Clinical Trial

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia(CIT) in Patients With Acute Myeloid Leukemia

Study acronym: H-CIT-AML
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 13, 2023 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
Randomized, controlled, open study to evaluate the efficacy and safety of Hetrombopag in the treatment of chemotherapy-induced thrombocytopenia(CIT) in patients with acute myeloid leukemia
Trial Details
NCT Number NCT05944211
Lead Sponsor RenJi Hospital
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Chemotherapy-Induced Thrombocytopenia
Enrollment 72 participants
Start Date 2023-07
Primary Completion 2026-07 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2023-07-13